Описание деятельности
The Group managed by 4SC AG (ISIN DE000A14KL72) discovers and develops targeted, small-molecule drugs for treating diseases with high unmet medical needs in various cancer and autoimmune indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies.
Правление & Наблюдательный совет
| Исполнительный директор |
| Dr. Jason Loveridge |
| Правление |
| Dr. med. Frank Hermann, Dr. med. Susanne Danhauser-Riedl |
| Наблюдательный совет |
| Dr. Clemens Doppler, Joerg von Petrikowsky, Dr. Irina Antonijevic, Dr. Manfred Rüdiger, Helmut Jeggle, Prof. Dr. Helga Rübsamen-Schaeff |
Данные компании
| Имя: |
4SC AG |
| Адрес: |
Fraunhoferstraße 22,D-82152 Planegg-Martinsried |
| Телефон: |
+49-89-700763-0 |
| Факс: |
+49-89-700763-29 |
| E-mail: |
-
|
| Интернет: |
www.4sc.de |
| Индустрия: |
Healthcare |
| Сектор: |
Pharmaceutical Industry |
| Подсектор: |
Pharmaceuticals |
| Конец финансового года: |
31.12 |
| Акции в свободном обращении: |
26.00% |
| Дата IPO: |
15.12.2005 |
Связи с инвесторами
| Имя: |
- |
| IR телефон: |
- |
| IR-факс: |
- |
| IR e-mail: |
ir-pr@4sc.com
|
